Exelixis, Inc. (NASDAQ: EXEL) Stock Competitors & Peer Comparison

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, VRTX has a market cap of 138.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while VRTX trades at $546.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas VRTX's P/E ratio is 28.79. In terms of profitability, EXEL's ROE is +0.46%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, EXEL is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check VRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MRNA has a market cap of 100.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MRNA trades at $247.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MRNA's P/E ratio is -30.78. In terms of profitability, EXEL's ROE is +0.46%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, EXEL is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MRNA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, REGN has a market cap of 94.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while REGN trades at $953.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas REGN's P/E ratio is 20.08. In terms of profitability, EXEL's ROE is +0.46%, compared to REGN's ROE of +0.15%. Regarding short-term risk, EXEL is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check REGN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas VRNA's P/E ratio is -102.80. In terms of profitability, EXEL's ROE is +0.46%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, EXEL is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check VRNA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ARGX has a market cap of 57.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ARGX trades at $973.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ARGX's P/E ratio is 35.03. In terms of profitability, EXEL's ROE is +0.46%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, EXEL is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ARGX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ONC has a market cap of 45.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ONC trades at $420.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ONC's P/E ratio is 74.65. In terms of profitability, EXEL's ROE is +0.46%, compared to ONC's ROE of +0.18%. Regarding short-term risk, EXEL is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ONC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas SGEN's P/E ratio is -57.19. In terms of profitability, EXEL's ROE is +0.46%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, EXEL is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check SGEN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RVMD has a market cap of 41.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RVMD trades at $180.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RVMD's P/E ratio is -21.89. In terms of profitability, EXEL's ROE is +0.46%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, EXEL is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check RVMD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RVMDW has a market cap of 39.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RVMDW trades at $8.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, EXEL's ROE is +0.46%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, EXEL is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RVMDW's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, GMAB has a market cap of 33.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while GMAB trades at $53.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas GMAB's P/E ratio is 40.75. In terms of profitability, EXEL's ROE is +0.46%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, EXEL is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check GMAB's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ROIV has a market cap of 29.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ROIV trades at $41.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ROIV's P/E ratio is -39.19. In terms of profitability, EXEL's ROE is +0.46%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, EXEL is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ROIV's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while INSM trades at $119.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas INSM's P/E ratio is -42.37. In terms of profitability, EXEL's ROE is +0.46%, compared to INSM's ROE of -0.83%. Regarding short-term risk, EXEL is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check INSM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while UTHR trades at $596.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas UTHR's P/E ratio is 21.06. In terms of profitability, EXEL's ROE is +0.46%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, EXEL is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check UTHR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, INCY has a market cap of 24.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while INCY trades at $122.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas INCY's P/E ratio is 16.17. In terms of profitability, EXEL's ROE is +0.46%, compared to INCY's ROE of +0.07%. Regarding short-term risk, EXEL is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check INCY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BNTX has a market cap of 21.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BNTX trades at $87.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BNTX's P/E ratio is -11.31. In terms of profitability, EXEL's ROE is +0.46%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, EXEL is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check BNTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ALNY has a market cap of 21B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ALNY trades at $157.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ALNY's P/E ratio is 7.91. In terms of profitability, EXEL's ROE is +0.46%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, EXEL is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ALNY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BGNE's P/E ratio is -22.55. In terms of profitability, EXEL's ROE is +0.46%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, EXEL is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check BGNE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.46%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, EXEL is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check DNA-WT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, NBIX has a market cap of 17.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while NBIX trades at $173.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas NBIX's P/E ratio is 24.44. In terms of profitability, EXEL's ROE is +0.46%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, EXEL is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check NBIX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ASND trades at $257.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ASND's P/E ratio is -106.01. In terms of profitability, EXEL's ROE is +0.46%, compared to ASND's ROE of +1.90%. Regarding short-term risk, EXEL is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ASND's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, JAZZ has a market cap of 15.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while JAZZ trades at $247.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas JAZZ's P/E ratio is 9.15. In terms of profitability, EXEL's ROE is +0.46%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, EXEL is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check JAZZ's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BBIO trades at $79.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BBIO's P/E ratio is -25.88. In terms of profitability, EXEL's ROE is +0.46%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, EXEL is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check BBIO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while SMMT trades at $16.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas SMMT's P/E ratio is -15.92. In terms of profitability, EXEL's ROE is +0.46%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, EXEL is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check SMMT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas KRTX's P/E ratio is -28.09. In terms of profitability, EXEL's ROE is +0.46%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, EXEL is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check KRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, HALO has a market cap of 11.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while HALO trades at $101.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas HALO's P/E ratio is 19.21. In terms of profitability, EXEL's ROE is +0.46%, compared to HALO's ROE of +5.44%. Regarding short-term risk, EXEL is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check HALO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, KYMR has a market cap of 11.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while KYMR trades at $135.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas KYMR's P/E ratio is -37.75. In terms of profitability, EXEL's ROE is +0.46%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, EXEL is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check KYMR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TECH trades at $72.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TECH's P/E ratio is 37.54. In terms of profitability, EXEL's ROE is +0.46%, compared to TECH's ROE of +0.08%. Regarding short-term risk, EXEL is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TECH's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RNAM's P/E ratio is -17.39. In terms of profitability, EXEL's ROE is +0.46%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, EXEL is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RNAM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BMRN trades at $58.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BMRN's P/E ratio is 27.47. In terms of profitability, EXEL's ROE is +0.46%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, EXEL is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check BMRN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PCVX has a market cap of 10.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PCVX trades at $68.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PCVX's P/E ratio is -8.70. In terms of profitability, EXEL's ROE is +0.46%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, EXEL is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PCVX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MDGL has a market cap of 10B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MDGL trades at $433.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MDGL's P/E ratio is -33.80. In terms of profitability, EXEL's ROE is +0.46%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, EXEL is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MDGL's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TGTX trades at $64.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TGTX's P/E ratio is 23.28. In terms of profitability, EXEL's ROE is +0.46%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, EXEL is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check TGTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while SYRE trades at $106.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas SYRE's P/E ratio is -53.55. In terms of profitability, EXEL's ROE is +0.46%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, EXEL is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check SYRE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RXDX's P/E ratio is -56.47. In terms of profitability, EXEL's ROE is +0.46%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RXDX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PRAX has a market cap of 9.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PRAX trades at $348.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PRAX's P/E ratio is -26.11. In terms of profitability, EXEL's ROE is +0.46%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, EXEL is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PRAX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas NUVL's P/E ratio is -21.79. In terms of profitability, EXEL's ROE is +0.46%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, EXEL is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check NUVL's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, KRYS has a market cap of 9.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while KRYS trades at $308.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas KRYS's P/E ratio is 38.41. In terms of profitability, EXEL's ROE is +0.46%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, EXEL is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check KRYS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CRNX's P/E ratio is -16.86. In terms of profitability, EXEL's ROE is +0.46%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, EXEL is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CRNX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PTGX trades at $134.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PTGX's P/E ratio is 132.29. In terms of profitability, EXEL's ROE is +0.46%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, EXEL is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PTGX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas IMGN's P/E ratio is -111.55. In terms of profitability, EXEL's ROE is +0.46%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, EXEL is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check IMGN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TWST has a market cap of 8.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TWST trades at $126.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TWST's P/E ratio is -59.52. In terms of profitability, EXEL's ROE is +0.46%, compared to TWST's ROE of -0.30%. Regarding short-term risk, EXEL is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check TWST's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas APGE's P/E ratio is -31.19. In terms of profitability, EXEL's ROE is +0.46%, compared to APGE's ROE of -0.30%. Regarding short-term risk, EXEL is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check APGE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BPMC's P/E ratio is -51.58. In terms of profitability, EXEL's ROE is +0.46%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check BPMC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CERE's P/E ratio is -16.47. In terms of profitability, EXEL's ROE is +0.46%, compared to CERE's ROE of -0.72%. Regarding short-term risk, EXEL is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CERE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ABVX has a market cap of 7.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ABVX trades at $91.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ABVX's P/E ratio is -14.74. In terms of profitability, EXEL's ROE is +0.46%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, EXEL is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ABVX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RYTM has a market cap of 7.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RYTM trades at $114.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RYTM's P/E ratio is -36.64. In terms of profitability, EXEL's ROE is +0.46%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, EXEL is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check RYTM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CYTK trades at $58.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CYTK's P/E ratio is -7.78. In terms of profitability, EXEL's ROE is +0.46%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, EXEL is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check CYTK's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TXG has a market cap of 7.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TXG trades at $63.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TXG's P/E ratio is -106.61. In terms of profitability, EXEL's ROE is +0.46%, compared to TXG's ROE of -0.08%. Regarding short-term risk, EXEL is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check TXG's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MTSR's P/E ratio is -23.58. In terms of profitability, EXEL's ROE is +0.46%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, EXEL is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MTSR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, AXSM has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while AXSM trades at $148.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas AXSM's P/E ratio is -36.81. In terms of profitability, EXEL's ROE is +0.46%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, EXEL is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check AXSM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, IMVT has a market cap of 7.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while IMVT trades at $37.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas IMVT's P/E ratio is -12.66. In terms of profitability, EXEL's ROE is +0.46%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, EXEL is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check IMVT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ORKA has a market cap of 7.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ORKA trades at $106.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ORKA's P/E ratio is -56.44. In terms of profitability, EXEL's ROE is +0.46%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, EXEL is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ORKA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, IBRX has a market cap of 7.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while IBRX trades at $6.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas IBRX's P/E ratio is -6.95. In terms of profitability, EXEL's ROE is +0.46%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, EXEL is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check IBRX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ARWR has a market cap of 6.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ARWR trades at $49.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ARWR's P/E ratio is -21.78. In terms of profitability, EXEL's ROE is +0.46%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, EXEL is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ARWR's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CAI trades at $24.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CAI's P/E ratio is 68.64. In terms of profitability, EXEL's ROE is +0.46%, compared to CAI's ROE of +0.16%. Regarding short-term risk, EXEL is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check CAI's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MRUS's P/E ratio is -17.05. In terms of profitability, EXEL's ROE is +0.46%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, EXEL is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MRUS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, KOD has a market cap of 6.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while KOD trades at $109.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas KOD's P/E ratio is -25.91. In terms of profitability, EXEL's ROE is +0.46%, compared to KOD's ROE of -2.73%. Regarding short-term risk, EXEL is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check KOD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ACLX's P/E ratio is -28.27. In terms of profitability, EXEL's ROE is +0.46%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, EXEL is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ACLX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RETA's P/E ratio is -66.29. In terms of profitability, EXEL's ROE is +0.46%, compared to RETA's ROE of +0.47%. Regarding short-term risk, EXEL is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RETA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CGON has a market cap of 6.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CGON trades at $73.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CGON's P/E ratio is -27.00. In terms of profitability, EXEL's ROE is +0.46%, compared to CGON's ROE of -0.25%. Regarding short-term risk, EXEL is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check CGON's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, LGND has a market cap of 6.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while LGND trades at $318.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas LGND's P/E ratio is 34.49. In terms of profitability, EXEL's ROE is +0.46%, compared to LGND's ROE of +0.05%. Regarding short-term risk, EXEL is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check LGND's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CNTA's P/E ratio is -22.63. In terms of profitability, EXEL's ROE is +0.46%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, EXEL is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CNTA's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MANE has a market cap of 6.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MANE trades at $152.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MANE's P/E ratio is -47.31. In terms of profitability, EXEL's ROE is +0.46%, compared to MANE's ROE of -0.38%. Regarding short-term risk, EXEL is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MANE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while BLTE trades at $156.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas BLTE's P/E ratio is -83.70. In terms of profitability, EXEL's ROE is +0.46%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, EXEL is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check BLTE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MIRM trades at $94.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MIRM's P/E ratio is -6.49. In terms of profitability, EXEL's ROE is +0.46%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, EXEL is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check MIRM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TERN's P/E ratio is -51.41. In terms of profitability, EXEL's ROE is +0.46%, compared to TERN's ROE of -0.14%. Regarding short-term risk, EXEL is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check TERN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while SRRK trades at $46.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas SRRK's P/E ratio is -13.91. In terms of profitability, EXEL's ROE is +0.46%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, EXEL is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check SRRK's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CDTX's P/E ratio is -19.77. In terms of profitability, EXEL's ROE is +0.46%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, EXEL is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CDTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, EXEL's ROE is +0.46%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, EXEL is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ABCM's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ISEE's P/E ratio is -22.44. In terms of profitability, EXEL's ROE is +0.46%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, EXEL is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ISEE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while COGT trades at $29.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas COGT's P/E ratio is -15.00. In terms of profitability, EXEL's ROE is +0.46%, compared to COGT's ROE of -0.71%. Regarding short-term risk, EXEL is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check COGT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ERAS trades at $16.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ERAS's P/E ratio is -16.65. In terms of profitability, EXEL's ROE is +0.46%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, EXEL is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ERAS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PTCT trades at $64.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PTCT's P/E ratio is -45.81. In terms of profitability, EXEL's ROE is +0.46%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, EXEL is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PTCT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas APLS's P/E ratio is 38.35. In terms of profitability, EXEL's ROE is +0.46%, compared to APLS's ROE of +0.40%. Regarding short-term risk, EXEL is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check APLS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, EWTX has a market cap of 5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while EWTX trades at $47.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas EWTX's P/E ratio is -25.15. In terms of profitability, EXEL's ROE is +0.46%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, EXEL is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check EWTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TVTX trades at $51.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TVTX's P/E ratio is -115.53. In terms of profitability, EXEL's ROE is +0.46%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, EXEL is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check TVTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while DNTH trades at $89.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas DNTH's P/E ratio is -21.40. In terms of profitability, EXEL's ROE is +0.46%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, EXEL is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check DNTH's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ADPT has a market cap of 4.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ADPT trades at $30.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ADPT's P/E ratio is -73.77. In terms of profitability, EXEL's ROE is +0.46%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, EXEL is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ADPT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, IONS has a market cap of 4.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while IONS trades at $28.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas IONS's P/E ratio is -8.62. In terms of profitability, EXEL's ROE is +0.46%, compared to IONS's ROE of -1.20%. Regarding short-term risk, EXEL is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check IONS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while DFTX trades at $34.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas DFTX's P/E ratio is N/A. In terms of profitability, EXEL's ROE is +0.46%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, EXEL is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check DFTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas FOLD's P/E ratio is -161.00. In terms of profitability, EXEL's ROE is +0.46%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, EXEL is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check FOLD's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas AKRO's P/E ratio is -14.57. In terms of profitability, EXEL's ROE is +0.46%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, EXEL is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check AKRO's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ALPN's P/E ratio is -101.52. In terms of profitability, EXEL's ROE is +0.46%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, EXEL is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check ALPN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CRSP has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CRSP trades at $45.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CRSP's P/E ratio is -9.49. In terms of profitability, EXEL's ROE is +0.46%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, EXEL is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check CRSP's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RLAY has a market cap of 4.4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RLAY trades at $19.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RLAY's P/E ratio is -12.70. In terms of profitability, EXEL's ROE is +0.46%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, EXEL is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check RLAY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas OPT's P/E ratio is -1.52. In terms of profitability, EXEL's ROE is +0.46%, compared to OPT's ROE of +1.18%. Regarding short-term risk, EXEL is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check OPT's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PRTC's P/E ratio is -3.78. In terms of profitability, EXEL's ROE is +0.46%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, EXEL is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PRTC's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas MRTX's P/E ratio is -4.82. In terms of profitability, EXEL's ROE is +0.46%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, EXEL is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check MRTX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while TNGX trades at $25.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas TNGX's P/E ratio is -29.28. In terms of profitability, EXEL's ROE is +0.46%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, EXEL is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check TNGX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ABCL has a market cap of 4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ABCL trades at $12.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ABCL's P/E ratio is -23.07. In terms of profitability, EXEL's ROE is +0.46%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, EXEL is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ABCL's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while XENE trades at $42.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas XENE's P/E ratio is -8.81. In terms of profitability, EXEL's ROE is +0.46%, compared to XENE's ROE of -0.40%. Regarding short-term risk, EXEL is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check XENE's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CPRX's P/E ratio is 17.49. In terms of profitability, EXEL's ROE is +0.46%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, EXEL is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CPRX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while AMLX trades at $31.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas AMLX's P/E ratio is -20.16. In terms of profitability, EXEL's ROE is +0.46%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, EXEL is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check AMLX's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while LEGN trades at $19.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas LEGN's P/E ratio is -30.01. In terms of profitability, EXEL's ROE is +0.46%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, EXEL is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check LEGN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while ELVN trades at $51.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas ELVN's P/E ratio is -30.66. In terms of profitability, EXEL's ROE is +0.46%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, EXEL is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check ELVN's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas RYZB's P/E ratio is -57.86. In terms of profitability, EXEL's ROE is +0.46%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, EXEL is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check RYZB's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas CBAY's P/E ratio is -32.81. In terms of profitability, EXEL's ROE is +0.46%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, EXEL is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for EXEL.Check CBAY's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, PBLS has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while PBLS trades at $29.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas PBLS's P/E ratio is -3.16. In terms of profitability, EXEL's ROE is +0.46%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, EXEL is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check PBLS's competition here

Exelixis, Inc. (NASDAQ: EXEL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EXEL stands at 17.7B. In comparison, IOVA has a market cap of 3.7B. Regarding current trading prices, EXEL is priced at $70.28 on the NASDAQ, while IOVA trades at $8.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EXEL currently has a P/E ratio of 20.17, whereas IOVA's P/E ratio is -11.07. In terms of profitability, EXEL's ROE is +0.46%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, EXEL is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for EXEL.Check IOVA's competition here